Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma

Haemophilia. 2010 Jan;16(1):185-7. doi: 10.1111/j.1365-2516.2009.02114.x. Epub 2009 Oct 5.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Hepatocellular / complications*
  • Carcinoma, Hepatocellular / drug therapy*
  • Chronic Disease
  • Factor VIII / administration & dosage
  • Hemophilia A / complications*
  • Hemophilia A / drug therapy
  • Hepatitis B / complications
  • Hepatitis C / complications
  • Humans
  • Liver Neoplasms / complications*
  • Liver Neoplasms / drug therapy*
  • Male
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use*
  • Sorafenib
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Factor VIII
  • Sorafenib